We are live on ! Find out more
BSPM

Biostar Pharmaceuticals, Inc.
BSPM

Delisted

BSPM was delisted on the 18th of September, 2018.

Back to rankings

7 hedge funds and large institutions have $189K invested in Biostar Pharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 7 → 7 (0)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

43% less capital invested

Capital invested by funds: $330K → $189K (-$141K)

Holders
7
Holders Change
–
Holders Change %
0%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$9.77K
2
Barclays
Barclays
United Kingdom
+$1.39K
3
Deutsche Bank
Deutsche Bank
Germany
+$1.05K

Top Sellers

Rank Fund Capital Flow
1
AIM
Acrospire Investment Management
Illinois
-$53.3K
2
JP Morgan Chase
JP Morgan Chase
New York
-$34.6K
3
UBS Group
UBS Group
Switzerland
-$3.74K
4
Morgan Stanley
Morgan Stanley
New York
-$588

BSPM Hedge Fund Activity: Q1 2017 in Review

7 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q1 2017, worth a combined $189K — down 43% from $330K a quarter earlier.

Fund positioning in BSPM was balanced in Q1 2017: 0 funds opened new positions, 0 closed out, 3 added to existing stakes and 4 trimmed.

The largest buyer was Acadian Asset Management, adding an estimated $9.77K. The largest seller was Acrospire Investment Management, cutting an estimated $53.3K.

  • 7 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q1 2017, unchanged from Q4 2016.
  • Funds reported $189K of Biostar Pharmaceuticals, Inc. stock for Q1 2017, down 43% quarter-over-quarter.
  • 0 funds opened new Biostar Pharmaceuticals, Inc. positions in Q1 2017 and 0 closed out.
  • The largest Biostar Pharmaceuticals, Inc. buyer in Q1 2017 was Acadian Asset Management, an estimated $9.77K added.
  • The largest Biostar Pharmaceuticals, Inc. seller in Q1 2017 was Acrospire Investment Management, an estimated $53.3K sold.

Based on aggregated 13F filings for Q1 2017.